Clinical trial
A Prospective, Multicenter, Randomized, Blinded, Positive Parallel Control Study to Estimate the Efficacy and Safety of Levornidazole Disodium Phosphate for Injection in the Treatment of Postoperative Intra-Abdominal Infections Caused by Anaerobic Bacteria
NCT06828874 is registered in ClinicalTrials.gov with Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multicenter, Randomized, Blinded, Positive Parallel Control Study to Estimate the Efficacy and Safety of Levornidazole Disodium Phosphate for Injection in the Treatment of Postoperative Intra-Abdominal Infections Caused by Anaerobic Bacteria
- Lead sponsor
- Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- May 10, 2023
- Completion date
- October 14, 2024
- Enrollment
- 696 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.